Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

Kader, Yasser Abdel; El-Nahas, Tamer; Sakr, Amr

doi:10.2147/ott.s48397

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from Egypt compared anthracycline-based chemotherapy with or without docetaxel in estrogen receptor-positive pT1-2 BC (n = 60). The addition of taxanes did not improve the 4-year disease-free survival [39]. …”

Section: Surgery and Adjuvant Treatment Of Bcmentioning

confidence: 99%

A Review on Breast Cancer Care in Africa

et al. 2015

View full text Add to dashboard Cite

Background: The global incidence of breast cancer (BC) is rising, especially in low- and middle-income countries. The purpose of this review is to summarize existing publications on BC care in Africa. Patients and Methods: A systematic search in MEDLINE and smaller databases was carried out to identify African studies on BC treatment, and an additional PubMed search was performed for relevant topics on BC care. Results: A total of 219 publications, mainly from North and West Africa, were found by systematic search. We also selected articles on BC epidemiology, risk factors, clinical presentation, and cancer control in Africa. Conclusions: Publications on BC treatment are mostly from hospital case series. Evidence on treatment from prospective randomized trials that address the specific characteristics of African patients is lacking. The epidemiologic data shows rising incidences in Africa. The prevalence of risk factors is changing by age group, geographic region, and over time. The clinical picture of BC differs from that of Western countries due to the high proportion of young patients (on account of the African population with a high proportion of young people) and late presentation. Global collaborative efforts are needed to address the rising need for improved BC care in Africa.

show abstract

Section: Surgery and Adjuvant Treatment Of Bcmentioning

confidence: 99%

A Review on Breast Cancer Care in Africa

et al. 2015

View full text Add to dashboard Cite

show abstract

“… 1 Taxane chemotherapy improved the breast cancer patient outcomes in the adjuvant setting. 2 However, in some studies, the benefit was difficult to evaluate because because of biologically heterogeneous populations and other factors, compared with anthracycline control regimens. 2 Docetaxel is used for treating patients with locally advanced or metastatic breast cancer and/or with unsuccessful anthracycline-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“… 2 However, in some studies, the benefit was difficult to evaluate because because of biologically heterogeneous populations and other factors, compared with anthracycline control regimens. 2 Docetaxel is used for treating patients with locally advanced or metastatic breast cancer and/or with unsuccessful anthracycline-based chemotherapy. 3 The drug promotes tubulin polymerization and stabilizing microtubule assembly, and prevents physiological microtubule dynamics.…”

Section: Introductionmentioning

confidence: 99%

Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

Kiba¹,

Morii²,

Takahashi³

et al. 2015

BCTT

View full text Add to dashboard Cite

We recently reported that neoadjuvant 5-FU, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel and/or trastuzumab induced a high pathological complete response (pCR) rate in hormone-negative patients. The present study examined the therapeutic efficacy of neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab in the treatment of hormone-positive patients. Between February 2012 and December 2013, 16 hormone-positive patients with local breast cancer (luminal A type: six patients; luminal B type: two patients; luminal HER2 type: eight patients) were included in the study. The histological type of the primary cancer was invasive ductal carcinoma in all patients. The cancer stages in the 16 women who received this regimen were stage I in five (31.3%), IIA in four (25.0%), IIB in five (31.3%), IIIB in one (6.3%), and IIIC in one (6.3%). Regarding clinical TNM classification, five patients were T1N0M0, one was T1N1M0, three were T2N0M0, five were T2N1M0, one was T3N2M0, and one was T4N0M0. The pCR was evaluated using resected tissue after neoadjuvant chemotherapy according to the evaluation criteria of the Japanese Breast Cancer Society. Patients were classified into pathologic responders (grade 2: 50.0% of all patients: 2/6 of luminal A type; 6/8 of Luminal HER2 type) and nonresponders (grades 0 and 1: 50.0% of all patients: 4/6 of luminal A type; 2/2 of luminal B type; 2/8 of luminal HER2 type) according to the grade of the tumor. The pCR rate was 0%. Hematologic and nonhematologic toxicity was reversible and manageable. This study demonstrated that neoadjuvant FEC followed by triweekly docetaxel and/or trastuzumab did induce a high pathologic response in luminal HER2 type, but not in luminal A and B types, and did not induce a high pCR rate in the hormone-positive patients.

show abstract